Dr.Manoj S [M08551] – Trivandrum
The advent of Anti VEGF therapy has revolutionized the management of retinal and choroidal diseases and has been the cornerstone of treatment success over the last decade. However we now understand that this therapy has its own limitations in certain diseases and have learnt to be more prudent. Newer strategies and modifications have therefore evolved though some consensus is yet to be obtained. This course will address some of these issues and aims to explore these facets in common retinal pathology including AMD, DME , RVO, ROP. The uncommon applications as well as situations where anti VEGF therapy was harmful will be shared with case examples by the experts.The current debate on the safety and legality of AVASTIN and biosimilars will also be addressed.
| 1 | Has AMD management changed these days (10 mins) | Dr.George J Manayathja | watch video |
| 2 | The DME affair ; loading protocols vs PRN, when to stop or modify (10 mins) | Dr.Rodney John Morris | watch video |
| 3 | Anti VEGF in RVO; is steroid a better option? (10 mins) | Dr.Anand Rajendran | watch video |
| 4 | The ROP debate; is it too premature? (10 mins) | Dr.Anubhav Goyal | watch video |
| 5 | I use them in all (varied case scenarios) (5 mins) | Dr.George J Manayath | watch video |
| 6 | I burnt my finger in some (varied case scenarios) (5 mins) | Dr.Anand Rajendran | watch video |
| 7 | Injection endophthalmitis; A word of caution (10 mins) | Dr.Unnikrishnan Nair R | watch video |
| 8 | Biosimilars; Can we use them yet? (5 mins) | Dr.Manoj S | watch video |
| 9 | Keynote Address by Navigated Laser Technology for the Treatment ofMacular Pathology( 10 mins ) | Dr.Pavel Volodin | watch video |
| Panel Discussion : (10 Mins) |


Leave a Comment